Article info
Current controversy
What’s yours is ours: waiving intellectual property protections for COVID-19 vaccines
- Correspondence to Dr Nancy S Jecker, Department of Bioethics & Humanities, University of Washington School of Medicine, Seattle, Washington, USA; nsjecker{at}uw.edu
Citation
What’s yours is ours: waiving intellectual property protections for COVID-19 vaccines
Publication history
- Received April 29, 2021
- Accepted June 22, 2021
- First published July 7, 2021.
Online issue publication
January 18, 2022
Article Versions
- Previous version (10 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage
Other content recommended for you
- Intellectual property waiver for covid-19 vaccines will advance global health equity
- Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine
- Threat of compulsory licences could increase access to essential medicines
- The COVID-19 vaccine patent: a right without rationale
- Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries
- Global equitable access to vaccines, medicines and diagnostics for COVID-19: The role of patents as private governance
- Pandemic preparedness and response: beyond the Access to COVID-19 Tools Accelerator
- Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
- The free trade agreement between Australia and the United States
- Trade is central to achieving the sustainable development goals: a case study of antimicrobial resistance